A year ago, the impact of COVID-19 vaccines was at the forefront of everybody’s minds. Our base case was that they would be effective, become widely available and allow the economy to recover, which proved largely accurate. However, COVID-19 very much remains with us, as the emergence of the new Omicron variant has reminded us.
To read this article, you need a subscription to Investment Officer. If you don't have a subscription yet, click on 'Subscribe' to see the various subscription options.
